Mind the gap - connected by quality. 4th - 6th November 2026, London.
More information
RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More informationThe MHRA and NICE now offer a joined-up scientific advice service to help medicine developers align regulatory and health technology assessment evidence needs early in development.
UK medical device testing hits record high as MHRA backs growth in brain and AI technology
Consultation open: 11/02/2026 to 11/04/2026
Consultation dates: 09/02/2026 to 09/04/2026
he European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) published outcomes from its February 2026 plenary meeting, covering new product opinions, variations, pharmacovigilance updates and draft guidance.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded a major safety review and issued key risk-management recommendations for human medicines.
WHO Member States have shown strong unity in advancing negotiations on a critical annex to the global Pandemic Agreement aimed at improving pandemic preparedness and equity.
The MHRA is consulting on proposals to allow CE-marked medical devices to be recognised indefinitely in Great Britain.
The International Council for Harmonisation (ICH) has published a mock example to help stakeholders understand the revised quality modules in the updated CTD guideline.
MHRA has published expected timelines for when CE-marked medical devices and IVDs can continue to be accepted in Great Britain.